RECURSION PHARMACEUTICALS, INC.: ARK Investment Management LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
ARK Investment Management LLC amended its Schedule 13G filing for Recursion Pharmaceuticals, Inc., updating its beneficial ownership stake with the SEC under accession number 0001104659-26-126833. The filing, submitted on Form 13G, reflects a change to ARK's previously reported position in the clinical-stage biotech company. Schedule 13G amendments are typically filed when an investor's ownership percentage crosses certain thresholds or when previously reported information becomes stale. The update matters because ARK's flagship innovation-focused funds are closely watched by retail and institutional investors, and shifts in their biotech holdings can signal changing conviction in the sector. Investors will watch for further 13G or 13F disclosures to confirm whether the amendment reflects an increase, decrease, or passive rebalancing of ARK's position in Recursion.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
ARK Investment Management LLC, Recursion Pharmaceuticals, Inc.